Abstract | Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. Skin biopsies of affected skin show a lymphocytic infiltrate in and around the bulb or the lower part of the hair follicle in the anagen (hair growth) phase. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata. Genetic studies in patients and mouse models have shown that alopecia areata is a complex, polygenic disease. Several genetic susceptibility loci were identified to be associated with signalling pathways that are important to hair follicle cycling and development. Alopecia areata is usually diagnosed based on clinical manifestations, but dermoscopy and histopathology can be helpful. Alopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the near future. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17011 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d . . The prevalence of alopecia areata in the early 1970s was reported to be between 0.1% and 0.2%, with a lifetime incidence of 1.7%
Alopecia areata is a common type of hair loss or alopecia in humans; it is an autoimmune disease with a vari able, typically relapsing or remitting, course that can be persistent -especially when hair loss is extensive. Alopecia areata is the second-most frequent nonscarring alopecia, after male and female pattern alopecia
. Clinical patterns of hair loss in alopecia areata are usually very distinct. The most common pattern is a small round or patchy bald lesion (patchy alopecia areata), usually on the scalp, that can progress to total loss of scalp hair only (alopecia totalis) and total loss of all body hair (alopecia universalis)
.
Historically, numerous hypotheses on the cause (or causes) of alopecia areata have been proposed, such as infection, a trophoneurotic hypothesis (based on the association between the time of onset of alopecia areata and emotional or physical stress and/or trauma), thallium acetate poisoning (owing to a similar clin ical presen tation), thyroid disease and hormonal fluctuations (for example, in pregnancy or menopause). Inflammation of the hair follicles in alopecia areata mediated by leukocytes was described over a century ago; yet, the involvement of the immune system in the pathogenesis of alopecia areata has only been recognized as the primary underlying cause since the late 1950s, when several immune-related and several key pathogenetic effector cells were identified 1, 2 . The formation of the National Alopecia Areata Registry 3 in the United States in 2000 provided access to data and clinical samples from >10,000 patients. The registry enabled the application of genome-wide association studies (GWAS) that have identified candidate genes associated with susceptibility to alopecia areata 4 , as well as an evaluation of important epidemiological and socio-medical issues, such as quality of life (QOL) 5 .
Concurrently, rodent models 6-8 that faithfully recapitulate the disease in humans and have enabled functional studies have been identified, and quantitative trait locus (QTL) mapping (a technique that links variations in DNA to phenotype) 9,10 has been performed. Together, all these techniques and associated observations have now firmly established that alopecia areata is a complex, polygenic, immune-mediated disease that can now be interrogated to identify biomarkers to differentiate its severity or subtypes 11 . In this Primer, we describe the current knowledge on the epidemiology of alopecia areata from a global perspective, the underlying pathophysiology, the genetic basis of this complex disease, concurrent diseases (comorbidities), diagnostic approaches, differential diagnoses and the current treatment approaches, as well as new breakthroughs.
Epidemiology A high degree of phenotypic and genotypic variability is observed in alopecia areata, which is a complex genetic disease determined by genetic and environmental factors. The reported prevalence, age of onset, history and concurrent diseases vary widely. Studies performed in a small number of patients should be viewed with caution.
Incidence and prevalence
Alopecia areata affects approximately 2% of the general population at some point during their lifetime, as documented by several large epidemiological studies from Europe 12 , North America 13 and Asia 14, 15 . The prevalence of alopecia areata in the early 1970s was reported to be between 0.1% and 0.2%, with a lifetime incidence of 1.7% 16 . One study in Olmsted County (Minnesota, USA), based on data collated between 1975 and 1989 from patients with alopecia areata who were seen by a dermatologist, showed that the overall incidence was 20.2 per 100,000 person-years, did not change with time and had no sexual dichotomy 17 . A follow-up study of this population from 1990 to 2009 found that the cumulative incidence increased almost linearly with age and that the lifetime incidence of alopecia areata was 2.1% 18 .
Although it is generally considered that there is no sexual dichotomy 17, 19 , some studies show that the prevalence seems to shift to women >45 years of age [20] [21] [22] . This skewed incidence might be an artefact as women might seek more medical attention as they age than men. Indeed, other population surveys suggest that alopecia areata is slightly more common in men 22 . One study found that men were more likely to be diagnosed at an earlier age than women 21 . No studies have determined if the prevalence of alopecia areata is different between ethnic groups 23 . Most studies report no significant differences in the age of onset, duration or type of alopecia areata by sex or ethnicity 19 . The onset of alopecia areata might be at any age; however, most patients develop the condition before 40 years of age, with a mean age of onset between 25 and 36 years 19 . Early-onset alopecia areata (a mean age of onset between 5 and 10 years) predominantly presents as a more severe subtype, such as alopecia universalis 19, [24] [25] [26] [27] 
Genetic factors
Several lines of evidence support the notion that alopecia areata has a genetic basis. In general, the prevalence of adult patients with a family history is estimated to be between 0% and 8.6% 28, 29 , whereas, in children, the data have been reported between 10% and 51.6% [24] [25] [26] 30 . One study found that men were more likely to have a positive family history and are diagnosed at an earlier age than women 21 . The occurrence of the disease in identical twins [31] [32] [33] [34] [35] [36] , siblings 37 and families with several generations of affected individuals [38] [39] [40] indicates that alopecia areata has a heritable basis. Most of the early human genetic studies were candidate gene association studies, in which linkage to specific genes or groups of genes was the focus. These studies focused on the HLA class II (HLA-D) region on human chromosome 6 as the most likely region for genes that regulate susceptibil ity or resistance to alopecia areata 41 . Family-based linkage studies and GWAS analyses, which were greatly enabled by the repository of the National Alopecia Areata Registry 3 , identified linkage or association on many chromosomes, which suggests that alopecia areata is a very complex, polygenic disease 4, 42 . These results confirmed earlier QTL analysis studies using an alopecia areata mouse model, often with similar, if not identical, results 9, 10 .
Concurrent diseases
Alopecia areata is associated with several concurrent diseases (comorbidities) including depression, anxiety and several autoimmune diseases, such as thyroid disease (hyperthyroidism, hypothyroidism, goitre and thyroiditis), lupus erythematosus, vitiligo, psoriasis, rheumatoid arthritis and inflammatory bowel disease 19, 43 . The frequency of these concurrent diseases varies between geographically separate populations, which may suggest genetic variability within these different populations. A retrospective study in Taiwan found that patients with alopecia areata had higher hazard ratios for autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus and psori asis, within the 3-year follow-up period than healthy controls 44 . In addition, an increased prevalence of other forms of inflammatory skin disease, such as atopic dermatitis, vitiligo, psoriasis and lichen planus, were found compared with controls, suggesting that patients with alopecia areata are at increased risk of developing various T cell-driven inflammatory skin diseases 45 . Severe alopecia areata might be accompanied by nail changes 22 . Atopic diseases, such as sinusitis, asthma, rhinitis and especially atopic dermatitis, are also more common than expected in populations with alopecia areata 43 and are associated with early-onset and more-severe forms of hair loss. In a Korean population, atopic dermatitis was significantly more common in patients with earlyonset alopecia areata, whereas thyroid disease was the most common in late-onset disease 46 ; findings were similar in Sri Lanka 22 . In a review of 17 studies, investigators found higher odds of atopic dermatitis in patients with alopecia totalis or alopecia universalis than in those with patchy alopecia areata 47 . In a large-scale epidemio logical study in Taiwan, investigators found a correlation between prior herpes zoster outbreaks and alopecia areata exposure within 3 years, suggesting that stress might trigger alopecia areata 48 . Several studies, with or without controls, demonstrated a high prevalence of thyroid autoimmunity associated with alopecia areata 49 , whereas others found lower frequencies than in earlier studies, indicating that there is no need for detailed investigations into these diseases without a clinical history to suggest they are present 50 .
Mechanisms/pathophysiology Genetics Studies aimed at elucidating the complex genetics of alopecia areata have been undertaken by several groups using techniques ranging from candidate gene association studies to transcriptional profiling of affected skin to large GWAS. The initial genetic studies concentrated on single genes that were known to be involved in related autoimmune diseases. Interestingly, many of these genes did in fact have a role in alopecia areata, in addition to inflammatory bowel disease, multiple sclerosis, psoriasis and type 1 diabetes mellitus 51 . Owing to the focus on an autoimmune aetiology, the HLA region, which encodes MHC molecules in humans, was initially identified as a major contributor to the alopecia areata phenotype [51] [52] [53] [54] . The HLA region on chromosome 6 is one of the most gene-dense regions of the genome and encodes key immune regulators 55 . Recent GWAS meta-analyses have localized the HLA signal of alopecia areata largely to the HLA-DRB1 region.
Subsequent large-scale genetic studies have added to the list of genes associated with alopecia areata and further validated the role of the HLA region genes.
For example, the several GWAS analyses in humans have identified 14 genetic loci associated with alopecia areata, many of which are known to be involved in immune function 4, 53, 56 . One locus, in particular, harbour ing the genes encoding the natural killer (NK) cell receptor D (NKG2D; encoded by KLRK1) ligands NKG2DL3 (encoded by ULBP3) and retinoic acid early transcript 1L protein (encoded by RAET1L; also known as ULBP6), was uniquely implicated in alopecia areata and not in other autoimmune diseases, which suggests a key role in pathogenesis. Indeed, this has been borne out of functional immunological studies showing that CD8 + NKG2D
+ T cells are the major effectors of alopecia areata disease pathogenesis. The dependency of these cells on IL-15 signalling for their survival provided a rationale for using Janus kinase (JAK) inhibitors to target the downstream effectors of this pathway in developing new therapeutic approaches.
In addition, gene expression studies have been used to validate these genetic studies and to assess local gene expression changes in affected areas. These studies have also identified more genes whose expressions are changed during disease progression 9,10,57,58 . Gene
Box 1 | Primary hair loss disorders*
Non-scarring alopecias
Non-scarring types of alopecia (also known as non-cicatricial alopecias) refer to hair loss due to changes in the hair cycle, hair follicle size, hair breakage or a combination of these changes, with preservation of the hair follicle.
• Female pattern hair loss: similar to male pattern hair loss but is characterized by diffuse hair loss with preservation of the frontal hair line and less well-defined aetiology.
• Loose anagen syndrome: usually presents in childhood and occasionally in adults and is characterized by slightly thinned, unruly, non-growing hair.
• Male pattern hair loss (also known as androgenic alopecia): alopecia characterized by a receding hair line and diffuse hair loss at the crown that affects 50% of men by 50 years of age and is genetically determined (polygenic) and androgen-dependent. • Short anagen syndrome: usually presents in childhood and is characterized by a normal density and hair strength, but minimal hair growth.
• Telogen effluvium: excessive hair shedding, which presents either as an acute self-limiting form triggered by diverse events (for example, childbirth, febrile illness, major surgery and rapid weight loss) or as a chronic type that is sometimes associated with female pattern hair loss.
• Temporal alopecia triangularis: a disorder that presents in newborn or young children and is characterized by a triangular or lancet-shaped bald spot with normal hair numbers, but very few terminal hairs (most are vellus hairs).
• Tinea capitis: a curable disease caused by fungal infection that presents in children and is characterized by patchy hair loss with signs of scalp inflammation (such as erythema and scaling of the scalp, and hair shaft infection and the presence of fungi observed in pulled hair). • Traction alopecia: hair loss due to chronic mechanical traction from hair styling, which is reversible in the early stages but might become irreversible owing to follicular deletion as a result of sustained traction.
• Trichotillomania: a hair-pulling impulse control disorder that is characterized by irregular patches or tonsural pattern of hair loss with broken hairs that are firmly attached in the scalp.
Scarring alopecias
Scarring types of alopecia (also known as cicatricial alopecias) refer to forms of hair loss in which hair follicles are destroyed owing to inflammation or, rarely, malignancy (such as cutaneous lymphoma). Affected skin shows loss of follicular ostia (the openings of the hair follicle through which the hair fibre emerges through the skin), but the early stages might resemble alopecia areata.
• Central centrifugal cicatricial alopecia: a condition mainly seen in women of African ethnicity that is characterized by patchy scarring lesions starting at the posterior crown or vertex and extending in a centrifugal pattern along the scalp; the aetiology involves genetic and environmental factors, such as hair styling techniques.
• Chronic cutaneous lupus erythematosus: a subtype of lupus erythematosus that presents with a symptomatic patch that evolves into scaly, indurated papules and gradually forms ill-defined, irregular or round plaques with variable atrophy, follicular plugging, telangiectasia and depigmentation. • Folliculitis decalvans: inflammation of the hair follicle involving neutrophils and lymphocytes possibly as a reaction to Staphylococcus aureus colonization that is characterized by patchy scarring hair loss with pustular lesions at the margins and mainly affects men.
• Frontal fibrosing alopecia: a type of lichen planopilaris, but with a different pattern of hair loss (in the frontal and frontotemporal hair line and eyebrows), typically affecting postmenopausal women.
• Lichen planopilaris: a chronic inflammatory disease that causes permanent hair follicle destruction typically characterized by patchy hair loss on the scalp with discrete follicular erythema at the margins of bald patches and is sometimes associated with cutaneous and/or mucosal lichen planus (that is, non-infectious itchy rash). 
Genetic hair disorders
Although most genetic studies in both humans and mice focus on the autoimmune aspects of alopecia areata, the hair loss is largely due to hair shaft fragility and breakage. In the mouse model for alopecia areata, cysteine-rich secretory protein 1 (Crisp1) was identified as a candidate gene within the major alopecia areata locus Alaa1 using a combination of QTL analysis, shotgun proteomics 60, 61 and in situ hybridization 62 . Although the autoimmune-based inflammation might dysregulate the development and growth of the hair shaft, the lack of CRISP1 in C3H/HeJ mice, the inbred strain most severely affected by spontane ous alopecia areata, suggested that CRISP1 might be an important structural component of mouse hair that predisposes the hair shaft to diseases. Whether this protein has a role in the severity of human disease remains to be determined. Such findings suggest an even more complex genetic involvement, with genetic factors not only involved in disease initiation but also in the pleomorphic clinical presentation.
Pathodynamics of hair loss
The dynamics of hair growth (FIG. 1) are altered in patients with alopecia areata. An early study 63 found that hair loss was preceded by a large increase in the proportion of telogen hairs and an increase in the proportion of abnormal hair shafts, which resulted in increased fragility of the shaft (dystrophic hairs) compared with normal hair from unaffected patients. In normal circumstances, most hairs are in the anagen phase (which is typically divided into six stages: anagen I-VI) and dystrophic hairs are not a feature. In fact, the initial event in alopecia areata seemed to be a rapid progression of hair follicles from the anagen phase to the catagen and telogen phases. Follicles that were less severely affected remained in the anagen phase but produced dystrophic hair shafts that eventually underwent progression to the telogen phase. Biopsies from the margins of expanding lesions of alopecia areata contained large numbers of follicles in the catagen or early telogen phase 64 . Whether follicles attained telogen via normal catagen transition was not determined. The affected follicles do re-enter the anagen phase. Indeed, one study 65 showed that almost 58% of the hair follicles in patchy alopecia areata are in the anagen phase.
Exclamation point hairs (a type of dystrophic hairs) are a key characteristic of alopecia areata and are not normally seen in healthy controls 64 . Although exclamation point hairs might have a well-formed club root identical to that of a normal telogen hair, the root is often narrowed and club hairs fall out more readily than normal. These changes suggested defective anchoring of the hair within the follicle.
Peribulbar inflammation is commonly found around anagen follicles that are adjacent to the focal lesion 64 . Early lesions showed a reduction in the size of the follicle below the level of the sebaceous gland, with preservation of the section above the sebaceous gland and the gland itself. The entire follicle is smaller in long-standing disease. The smaller anagen follicle is mitotically active, prod ucing a normal inner root sheath. The hair shaft cortex is incompletely keratinized. These changes suggested that hair follicle developmental arrest occurs in the anagen IV phase 66 . Other histopathological studies largely confirmed this study 64, 65 . Indeed, horizontal biopsies from the centre of bald patches of patients with alopecia totalis or alopecia universalis found anagen follicles that had failed to develop beyond the anagen III/IV phase. The inner root sheath is a conical keratinized structure at this stage, and the hair cortex has just started to differentiate beneath it. Follicles seem to prematurely return to the telogen phase from the anagen III/IV phase and undergo repeated shortened cycles. As alopecia areata activity subsides, the hair follicles progress further into the anagen phase.
Immune response Target cell. The histopathological feature of alopecia areata is an inflammatory cell infiltrate concentrated in and around the bulbar region of anagen hair follicles (FIG. 2) . The hair follicle matrix epithelium that is undergoing early cortical differentiation seems to be the primary target of an immune attack on the hair follicle based on several lines of evidence. First, the matrix cells exhibit vacuolar degeneration (a type of non-lethal cell injury, which is characterized by small, intra-cytoplasmic vacuoles) in affected anagen follicles 67, 68 , which explains the formation of the exclamation point hair shaft. These degenerative changes lead to a localized region of weakness in the hair shaft, which results in the hair shaft breaking when it emerges from the ostium at the skin surface. Second, the affected hair follicles revert to the telogen phase, in which cortical differentiation does not occur. Follicles re-enter the anagen phase normally but do not develop beyond the anagen III/IV phase, the point at which cortical differentiation commences. Last, aberrant MHC class I and class II expression occurs in the pre-cortical region where the inflammatory cell infiltrates are localized 69 .
Breakdown of immune privilege. The hair follicle is an immune-privileged site that prevents auto immune responses against putative autoantigens that are expressed in the hair follicle 70 (FIG. 2a) . Under normal physiological conditions, a local immunoinhibitory signalling milieu in and around the hair follicle is generated that suppresses the surface molecules required for presenting autoantigens to NK cells, including CD8 + T lymphocytes. Although the function (or functions) of this immune privilege of hair follicles is not proven [71] [72] [73] [74] , it is believed that several autoantigens that are related with pigment production in melanocytes are immunogenic and, under the right circumstances, can result in loss of immune privilege 75 . The breakdown of the immune privilege of the hair follicle has been thought to be a major driver of alopecia areata ( + NK cells are found around hair follicles from patients with alopecia areata. The counts of a subset of CD56 + NK cells that express NK cell-activating receptors (such as NKG2D and NKG2C) were higher in peripheral blood cells of patients with alopecia areata than in healthy controls, whereas the killer cell immunoglobulin-like receptors 2D2 or 2D3 were lower 76 . GWAS confirmed these observations and linked polymorphisms in the ULBP gene cluster (encoding the NKG2D ligands) with susceptibility to alopecia areata 4, 42 , and functional studies showed overexpression of these genes in lesional hair follicles of patients with alope cia areata. Finally, the expression of receptors for vaso active intestinal peptide (VIPR1 and VIPR2), which are located in the hair follicle epithelium, was downregulated in hair bulbs of patients with alopecia areata compared with controls, but VIP ligand expression was normal in nerve fibres, which suggests that patients have defects in VIPR-mediated signalling 77 .
Autoantigen epitopes. The involvement of autoantigen epitopes in the initiation of alopecia areata has been hypothesized. An involvement of melanin, melaninrelated proteins and keratinocyte-derived antigens has been suggested based on the observation that white hairs grow back after a period of alopecia areata and are often spared in further relapses [78] [79] [80] [81] [82] . Administration of synthetic epitopes derived from trichohyalin (a structural protein) and tyrosinase-related protein 2 (now known as dopachrome tautomerase, which is involved in pigmentation) induced significantly higher cytotoxic T lymphocyte responses in patients with alopecia areata than in similarly stimulated peripheral blood mononuclear cells from normal control patients 83 .
Other contributing factors
Oxidative stress. Oxidative stress has a role in alopecia areata and other skin diseases 84, 85 . Significantly higher levels of malondialdehyde (an indicator of lipid peroxidation) and antioxidant activity of superoxide dismutase (SOD) were found in the blood of patients with alopecia areata than in healthy controls 86 . In another study, 32% of patients with alopecia areata had antibodies against reactive oxygen species-damaged SOD, whereas no appreci able reaction was found in normal patients 84 . This suggests that oxidative stress and damage to SOD play a part in the induction of alopecia areata. A limited genetic study did not find any association between alopecia areata and polymorphisms in SOD2 or GPX1 (which encodes glutathione peroxidase) 85 .
Vasculature and lymphatic system. In general, inflammation is often associated with an increased blood supply to the involved areas, which might include the development of new vessels, both blood vessels and lymphatic vessels. Clinical observations have revealed that alopecia areata lesions show increased skin temperature, which was interpreted to be the result of increased vascularization 87 . Other studies have suggested that defective monocytes isolated from patients with long-standing alopecia totalis and alopecia universalis decreased angiogenic activity relative to normal controls or patients with short-term alopecia areata 88 . Intralesional steroid administration, a common treatment for alopecia areata, resolves peri vasculitis and is associated with disease resolution 89 . These observations suggest that vascular changes in lesions have a role in the pathogenesis of this alopecia areata.
Cutaneous lymphatic density in mice declines as they age 90 . However, in a mouse model of alopecia areata (full-thickness skin grafts from C3H/HeJ mice with naturally occurring alopecia areata in younger, healthy C3H/HeJ mice, that is, the skin engraftment model), lymphatic dilation was found 20 weeks after engraftment. Transcriptome analysis of the skin from these mice revealed abnormal transcript levels of genes encoding proteins that acted directly or indirectly on the lymphatic system. Indirect effects included proteins involved in regulating blood pressure or regulating cellular components of the lymphatic fluid, including T cells, B cells and dendritic cells. Although lymphatic changes alone are a minor part of the pathogenesis of alopecia areata, these changes may collectively contribute to the pathogenesis when considering the ancillary effects beyond the lymphatic system. Identification of these transcripts, many of which do not initially seem to be involved with the autoimmune process, might result in potential new treatment targets 91 .
Microbiota. The role of the microbiota in the pathogenesis of various diseases is an emerging area of research. The C3H/HeJ mouse strain is not only a model for alopecia areata 8 but was also the first model found to develop a spontaneous form of inflammatory bowel disease 92 . Inflammatory bowel disease can be a comorbidity of alope cia areata in humans 93 . The mouse skin graft model for alopecia areata 94 showed variable results when performed at different geographical regions. Although this phenomenon was attributed to high levels of dietary soy bean phytoestrogens in the diet 95 , the microbiota might also have played a part. Therapeutic manipulation of the microbiota represents an innovative treatment option for many diseases, including alopecia areata, and is a subject for future research.
Environmental triggers
In the majority of cases, no obvious explanation for the onset of an episode of alopecia areata can be found, but various triggers have been proposed. The most commonly reported is emotional or physical stress, such as following bereavement or injury 19, 43 . Others include vaccinations, febrile illness and drugs. A low frequency of alopecia areata was reported to arise shortly after vaccinations against various human pathogens, including Japanese encephalitis virus 96 , hepatitis B virus 97 , Clostridium tetani 98 , herpes zoster virus 99 and papillomavirus 100 . By contrast, one report showed that alopecia areata was triggered or exacerbated by swine flu virus infection 101 . However, hepatitis B vaccine trials using a large number of C3H/HeJ spontaneous, adult-onset mouse models of alopecia areata, in which diphtheria and tetanus toxoids were added as controls, suggested that alopecia areata associated with vaccination was in the normal, predicted incidence range 102 .
Animal models
Although humans are usually the focus of biomedical research, a wide variety of mammals have been reported to develop alopecia areata. However, of all of these, only the laboratory mouse has held up as a useful species for mechanistic and preclinical studies 103, 104 . Animal models can be used to study disease onset, which is not possible in humans as it is currently not possible to predict During the anagen phase (the period the hair is actively growing), which can vary from a few weeks to several years, epithelial cells in the hair bulb undergo vigorous mitotic activity and differentiate as they move distally to form the hair fibre and its surrounding inner root sheath and inner layer of the outer root sheath. Eventually, epithelial cell division ceases, and the follicle enters the catagen phase, in which the proximal end of the hair shaft keratinizes to form a club-shaped structure, which eventually sheds, and the lower part of the follicle involutes by apoptosis. The telogen phase marks the period between follicular regression and the onset of the next anagen phase (solid arrows). The development of the anagen follicle, which closely replicates embryonic development of the hair follicle, is conventionally divided into six stages (anagen I-VI, with anagen VI representing the fully formed anagen follicle) 66 . In most mammals, hair cycles are coordinated in a wave-like manner across the skin (moult waves), but in humans, follicles cycle independently of their neighbours. In alopecia areata (dashed arrow), anagen VI follicles are precipitated prematurely into telogen phase. Although they are able to re-enter anagen phase, the development of the follicle is halted at the anagen III/IV stage 3,4 , when they prematurely return to the telogen phase. Truncated cycles may continue if and until disease activity declines, and follicles are able to progress further into the anagen phase. Bulb who will develop alopecia areata. Although there are biological differences between mouse and human skin (such as wave versus mosaic hair cycle and short versus long anagen stage), phylogenetic conservation is high, including similar diseases, such as alopecia areata 105, 106 . Peribulbar inflammation, a prominent feature of human alopecia areata, is often not found in the mouse owing to the very short anagen stage of the hair cycle in the mouse. In fact, in mice, the inflammation is usually observed above the bulb region but, as in human, is also is associated with upregulation of MHC class I molecules 107 . Both mice and humans with alopecia areata respond to the same types of treatments, both positively and negatively, further valid ating their usefulness as an animal model (reviewed in REFS 108, 109) .
Several C3H laboratory substrains develop alopecia areata spontaneously. Other inbred strains also develop the disorder, but the frequency of the disease is extremely low 110, 111 . Although C3H/HeJ mice carry a spontaneous mutation in the Toll-like receptor 4 (Tlr4 Lps-d ) gene 112 , the C3H/HeN mice are wild type (Tlr4 +/+ ) and otherwise genetically similar; this observation rules out the involvement of Tlr4 in the pathogenesis of alopecia areata as both substrains develop alopecia areata 8, 110 . CBA/CaHN-Btk xid /J mutant mice, a model of human X-linked immunodeficiency, occasionally develop spontaneous alopecia areata 110 . These mutant mice have a B lymphocyte-specific defect that results in their inability to launch an antibody response to thymus-independent type II antigens, which is a natural experiment indicating that alopecia areata is not a . Although nail abnormalities are found in a subpopulation of patients with alopecia areata, nail disorders are not found in the inbred mouse strains that develop this disease. However, a single case was reported in a recombinant inbred strain, which may prove to be a useful tool to investigate this phenomenon 110 .
To date, only the C3H substrains have been studied in detail. Spontaneously affected C3H/HeJ mice develop focal alopecia areata that can wax and wane to become generalized over time (FIG. 3a) . The hair loss is associated with structural defects in the hair shaft, which lead to breakage compared with normal hair shafts (FIG. 3b-g ). A mixture of CD4 + and CD8 + T cells exist in and around the hair follicles just above the bulb to the level of the sebaceous gland that are associated with follicular dystrophy 114 (FIG. 3h-k) .
Mouse models were used to identify various epitopes that seem to be specific for alopecia areata. MHC class I-restricted 1MOG244.1 CD8 + T cells in a normally resistant C57BL/6J mouse model are capable of independently producing effector responses that are necessary for the development and full progression of alopecia areata. The 1MOG244.1 T cell clone in this mouse model independently mediates alopecia areata and was proposed as a potential tool for antigen screening 115 . This was the first indication that a specific epitope might cause alopecia areata.
The relatively low frequency (20-25% penetrance), late disease onset, and waxing and waning course of spontaneous alopecia areata in C3H/HeJ mice 8 reduced the value of this mouse model as a research or preclinical tool. However, full-thickness skin grafts from affected, older C3H/HeJ to young, clinically normal C3H/HeJ female mice resulted in a highly reproducible model, in which the mice had diffuse alopecia areata by 10 weeks after engraftment and generalized baldness 20 weeks after engraftment 94, 116, 117 . Cells obtained from lymph nodes draining affected areas of skin, and even long-term cultures of these cells, can also be used to induce alopecia areata in young, histocompatible mice of the same strain 118 . This strategy has the advantage of circumventing skin graft surgery and to study the pathophysiology of alopecia areata at an early stage, before hair loss. Humanized mice with various mutations causing immunodeficiency that are implanted with human skin grafts with or without alopecia areata and given various types of human T cells are another model. Although it has been used successfully, this approach has very limited use to date owing to the difficulty of most groups getting access to human skin biopsies and/or peripheral blood leukocytes 119 . Finally, a rat model (that is, the Dundee experimental bald rat) was identified and studied in detail 7 , but this model is no longer used owing to its large size, the expense of maintaining colonies relative to mice and the limited reagents for working with rat samples 103 .
Diagnosis, screening and prevention

Clinical features
Initially, alopecia areata is diagnosed by identification of waxing and waning focal alopecia anywhere on the body but most often on the scalp (FIG. 4a,b) . Although the scalp is often the first affected site, any and all hair-bearing skin can be affected. Patches of hair loss within the beard can be conspicuous in dark-haired men. Likewise, eyebrows and eyelashes may be the only sites affected. The skin in the affected areas appears normal or slightly reddened (FIG. 4c) . Exclamation point hairs are often seen (part a) . Spontaneous alopecia development in C3H/HeJ mice starts with patchy alopecia areata in the axillary and inguinal regions, which spreads across the ventral skin to the dorsal skin and eventually results in diffuse alopecia. Note that the fine hair of the tail and ears is not involved. Analysis of the hair of C3H/HeJ mice with alopecia areata (parts b-e) and controls (part f and part g) is shown. Plucked hairs from sites adjacent to bald areas contain a mixture of relatively normal hairs with some that have bulbous deformities (parts b-e). The regular sepate or seputulate (ladder-like) pattern of the normal hair medulla (part f and part g) is lost and the hair shaft becomes thin and serpentine (parts b-e). These deformities weaken the hair and result in hair shaft breakage (parts b-e). Normal hair shafts from an unaffected C3H/HeJ mouse reveal the regular and strain septulate (three rows) and septate (one row) cellular pattern within the hair shafts (part f and part g). Parts c, e and g are enlargements of the boxes in parts b, d and f, respectively. Histopathological analysis of the skin is shown (parts h-k). Mice with alopecia areata have various degrees of inflammation and follicular dystrophy in and around the anagen hair shafts (parts h-j) . A healthy, late anagen stage hair follicle is shown in part k.
at the margins of these lesions during the active phases of the disease. Subsequent progress is unpredictable; the initial patch can expand or regrow hair within a few months, or further patches can appear after various time intervals. A succession of discrete patches may coalesce to give large areas of hair loss. In some cases, this progresses to alopecia totalis (FIG. 4d) or alopecia universalis; sometimes, specific areas are affected, such as in ophiasis (FIG. 4e) . In a minority of patients, hair loss is initially diffuse without the development of discrete bald patches. Regrowth may initially present as fine and nonpigmented hair, but usually the hairs gradually regain their normal thickness and colour. Regrowth in one region of the scalp may be associated with expanding areas of alopecia elsewhere 120, 121 . White (uncoloured) hairs are often spared in alopecia areata (FIG. 4f) . In those with a mixture of pigmented and non-pigmented hair, alopecia areata preferentially affects pigmented hair, resulting in sparing of the white hair that causes a dramatic change in hair colour if the alopecia progresses rapidly. Sparing of white hair is a relative phenom enon; white hairs, although less susceptible to the disease, are not immune to it. In a mouse model in which pigment loss was created in a focal manner using freeze branding, white hairs were not preferentially spared 122 . However, in humans, sparing of white hairs might reflect the effects of the autoimmune attack on the bulb region during the period when pigment is produced 68 . Alopecia areata can involve the nails, abnormalities of which are observed in about 10-15% of cases referred to a dermatologist and up to 44% in some populations [123] [124] [125] . Patients with nail problems usually exhibit the more severe forms of hair loss (50.5% of patients with severe alopecia areata have nail abnormalities versus 13% of patients with patchy alopecia areata; P < 0.01) 125 . Alopecia areata is usually associated with fine stippled pitting of the nails; some cases have less well-defined roughening of the nail plate with longitudinal striations (trachyonychia) (FIG. 4g) . The nail dystrophy can be the most troublesome aspect of the disease. In a large study of 1,000 patients with alopecia areata with nail lesions, only pitting was significantly found more often than other nail defects in children than in adults 125 .
Disease course and prognosis
The potential for regrowth of hair in patients with alope cia areata is retained for many years and is possibly lifelong, as the disease process does not destroy hair follicles. This is an important difference between alope cia areata and the scarring forms of alopecia, which destroy the hair follicle and result in irreversible hair loss
. The long-standing notion that patients with chronic alopecia totalis and alopecia universalis lose the ability to regrow hair probably stems from a historical difficulty in treatments by previously available topical and oral medications. Patches of hair loss may occur at infrequent intervals interspersed with long periods of complete remission. In other patients, alopecia areata is more persistent such that new areas of alopecia continue to develop as other areas resolve. Referral centres indicate that 34-50% of patients will recover spontaneously within 1 year, although most will experience multiple episodes of the alopecia, and 14-25% of patients will progress to alopecia totalis or alopecia universalis, from which full recovery is unusual (<10% of patients) 12, 13, 126 . One Japanese study reported spontaneous remission Nature Reviews | Disease Primers in 80% of patients within 1 year for those with a small number of circumscribed patches of hair loss 14 . The best indication for a prognosis is the extent of hair loss when first diagnosed 126 . A less favour able prognosis is observed with childhood-onset alopecia areata and ophiasis 126, 127 . A later age of onset correlates with less extensive alope cia 29, 128, 129 . Severe alopecia areata (alopecia totalis and alopecia universalis) usually occurs before 30 years of age 129 and is often associated with nail dystrophy (trachyonychia) [128] [129] [130] .
Classification of severity
Alopecia areata is conventionally classified as patchy, alopecia totalis and alopecia universalis (BOX 2) . A more detailed classification should include the disease duration and, with regard to patchy alopecia areata, the extent of the hair loss. Description of the pattern should include the presence of ophiasis, the involvement of sites on the trunk and limbs as well as the beard and eyelashes, and the presence of nail disease. A scoring system based on these features, the Severity of Alopecia Tool (SALT) score, has been devised 131 . An alopecia areata progression index was also developed, in which the scalp surface was divided into four quadrants. Hair loss in each quadrant was scored based on the percentage of hair lost and clinical findings 132 .
Investigations
The diagnosis of alopecia areata is usually made on clinical grounds, and, in most cases, further tests are not needed. However, numerous tools, such as dermoscopy or histopathology, can further validate the diagnosis (FIG. 5) .
Dermoscopy. The advent of dermoscopy (that is, examination of the skin using a skin surface microscope) provided an additional tool for the diagnosis of alopecia areata and differentiation from other hair loss disorders that can present in a similar manner 133 . The key dermoscopic features of alopecia areata are yellow dots, black dots, broken hairs, exclamation point hairs and short vellus hairs, which are a sign of early regrowth (FIG. 5a,b) .
Histopathology.
If there is diagnostic uncertainty, a skin biopsy might be necessary, although the histological features can be subtle; evaluation by an experienced pathologist is needed to confirm the diagnosis. A skin biopsy can be helpful to diagnose diffuse alopecia areata and to differentiate early scarring alopecia. Alopecia areata is a dynamic disease that is reflected in its histopathological features 64 (FIG. 5c,d ). Both transverse and horizontal sections are important to review to obtain an accurate histopathological diagnosis of alopecia areata.
In biopsies taken from the margin of an expanding bald patch, newly affected anagen follicles typically show a lymphocytic infiltrate around and within the hair bulb. Eosinophils and CD1 + and CD8 + cells can also be found within the infiltrate. A large increase in the number of follicles in the catagen and telogen phases is seen in the early stages of the disease. The catagen stage may be disorganized, with follicles containing remnants of disrupted hair fibres. Biopsies from established bald patches show a normal number of hair follicles that are devoid of terminal hair fibres. Follicles below the level of the sebaceous gland are miniaturized and have telogen or anagen morphology. However, the miniaturized follicles are limited to the early stages of anagen development. A peribulbar and intrabulbar inflammatory infiltrate is associated with anagen but not telogen follicles and tends to be less pronounced than in the initial stages of the disease. Other features include pigmentary incontinence (that is, melanin granules within dermal macrophages or free in the dermis secondary to epithelial cell injury) concentrated in follicular dermal papillae and degeneration of the hair bulb epithelium around the upper pole of the dermal papilla in anagen follicles 120 .
Differential diagnosis
Alopecia areata needs to be differentiated from other types of non-cicatricial alopecia, cicatricial alopecia and genetic conditions associated with hair loss
. In children, tinea capitis and trichotillomania are the most common diseases that are mistaken for alopecia areata. In addition, the early stages of scarring alopecia might be difficult to differentiate. The diffuse form of alopecia areata is perhaps the most difficult to identify and may require a detailed history to uncover previous episodes of hair loss, nail dystrophy and the usually rapid progression of the hair loss. The development of alopecia universalis in infancy should alert the clinician to the possibility of atrichia with papular lesions (also known as papular atrichia), which is due to rare, autosomal recessive mutations in the hairless (HR) 134 or the vitamin D receptor (VDR) genes 135 . Hair loss in patients with VDR mutations may also be partial. Besides specific differences in clinical presentation, additional investi gations, such as dermoscopy and histopathology, are helpful to differentiate these conditions from alopecia areata. On the basis of clinical suspicion, other diagnostic tests can include fungal culture, serology for systemic lupus erythematosus or serology for syphilis.
Management
General principles
Several treatments can induce hair growth in alopecia areata, but few have been tested in randomized controlled trials and there are few published data on long-term outcomes; none has been approved by the US FDA, although there are guidelines and treatment options available in other countries 136, 137 . Some patients do respond well to currently available treatments, but the response rate in those with severe alopecia areata types (alopecia totalis, alopecia universalis or a combination) remains low. A high level of immune reactivity is present in patients with alopecia totalis and alopecia universalis than in normal controls 11 . Not all patients need or wish for active treatment. Remission might occur spontaneously in patients with limited patchy hair loss of short duration (<1 year) 14, 126 . Although reassurance alone might be adequate in this patient group, advice should make clear that regrowth will take >3 months of the development of any individual patch. Long-standing extensive alopecia areata has a less favourable prognosis and, currently, all treatments have a high failure rate. These patients might prefer not to be treated or opt for cosmetic options. For many patients, the overriding issue is how to cope with ongoing or recurrent hair loss, and the clinician has an important role in helping patients to deal with this. Counselling should include an explanation of the nature of the disease and the disease course, the treatments available and their chances of success. Some patients might require psychological support.
Medical management
Local corticosteroids. A potent topical steroid (for example, clobetasol) delivered in a lotion, foam or shampoo formulation can be used for limited patchy alopecia areata and may speed recovery of hair growth in mild degrees of alopecia areata [138] [139] [140] . Treatment should be continued for at least 3 months, but should be stopped after 6 months if there is no response. Folliculitis (inflammation of the hair follicles) is an occasional complication. Topical steroids are ineffective to treat alopecia totalis and alopecia universalis.
Intralesional steroid application is probably the most effective treatment in patchy alopecia areata. A slowrelease steroid (such as hydrocortisone acetate or triamcino lone acetonide) administered by fine-needle injection or by a needleless device into the upper subcutaneous tissue can stimulate hair growth at the site of injection in some patients 141, 142 , but multiple injections are usually needed. Local cutaneous atrophy is a common adverse effect but recovers within a few months. Intralesional steroid administration will not prevent the development of alopecia areata at other sites and is not suitable for patients with rapidly progressive patchy alopecia areata, alopecia totalis or alopecia universalis. Mechanistic studies have revealed that the increased abundance of CD3 + T cells, CD8 + T cells, CD11c + dendritic cells and CD1a + Langerhans cells in and around hair follicles in alopecia areata decreased following intralesional corticosteroid treatment. In addition, downregulation of genes encoding several interleukins and chemokines (such as IL-12β, CC-chemokine ligand 18 and IL-32) and upregulation of genes encoding several keratins (KRT35, KRT75 and KRT86) were observed following intralesional steroid administration compared with levels before injection. These results suggest that these genes may be useful biomarkers for monitoring steroid treatment in patients with alopecia areata 143 . Various other treatments, such as topical minoxidil (a vasodilator) and anthralin (also known as dithranol; which has antiproliferative and anti-inflammatory effects), have been advocated in patients with limited patchy alopecia areata, but their benefits are uncertain 137 .
Systemic corticosteroids. Long-term daily treatment with oral corticosteroids might result in regrowth of hair, and this strategy has successfully been used for extensive and rapidly progressive alopecia areata. A small, partially controlled study showed that 30-47% of patients with mild-to-extensive alopecia areata who were treated with a 6-week tapering course of oral prednisolone showed >25% hair regrowth 144 . However, in most patients, continued treatment is needed to maintain hair growth and the response is usually insuffi cient to justify the adverse effects. Several case series have reported favourable responses to high-dose pulsed corticosteroid treatment using different oral and intravenous regimens [145] [146] [147] . However, the only controlled trial showed that patients receiving prednisolone once weekly for 3 months had better hair regrowth at 6 months than those taking a placebo, but this was not significant 148 .
Contact immunotherapy.
Contact immunotherapy is an effective treatment for some patients with patchy alopecia areata. The application of a potent allergen to a small area on the scalp sensitizes the patient. The same allergen, in a concentration that is sufficient to induce a mild contact dermatitis, is then applied weekly. Contact allergens used in this treatment include dinitro chlorobenzene, squaric acid dibutylester and diphenylcyclopropenone, with diphenylcyclopropenone being most commonly used. Although the mode of action of contact immunotherapy is unknown, antigens might induce 'antigenic competition' and attract CD4 + T cells away from the peri follicular region 149 . Other proposed mechanisms include the nonspecific stimulation of suppressor T cells in the skin 150 , increased local expression of transforming growth factor-β 151 and the activation of myeloid suppressor cells that, via ζ-chain downregulation, contribute to autoreactive T cell silencing 152 .
Although the published response rates vary widely (9-87%), in general, 20-30% of patients achieve a response that is considered to be worthwhile, such as sufficient regrowth to enable the patient to manage without a wig 153 . Less favourable responses were reported in patients with extensive hair loss 154, 155 . Adverse prognostic features include the presence of nail abnormalities, an early onset of alopecia, a positive family history and failure to sensitize (which does occur but is rare in our experience) 153 . Treatment is usually discontinued after 6 months if no response is obtained. One study showed clinically significant regrowth in approximately 30% and 78% of patients after 6 months and 32 months of treatment, respectively, suggesting that prolonged treatment is required to achieve a favourable outcome 156 . The response in patients with alopecia totalis and alopecia universalis was only 17%, which did not improve upon prolonged treatment beyond 9 months. Unfortunately, 62% of successfully treated patients showed relapse. In children, response rates of 33% 157 and 32% 158 have been reported. Another study found a similar short-term response in children with severe types of alopecia areata, but <10% experienced sustained benefit 159 . No long-term adverse effects have been reported that are associated with contact immunotherapy in >30 years of use. Severe dermatitis is the most common adverse event, but careful titration of the drug concentration can reduce the risk. Transient occipital and/or cervical lymphadenopathy are also frequent and can persist throughout the treatment period. Uncommon adverse effects include urticaria 160 and vitiligo 161 . In patients with racially pigmented skin, hyperpigmentation and hypopigmentation (including vitiligo) can occur. Health professional sensitization (doctors, nurses and pharmacy technicians involved in delivering contact immunotherapy) is a considerable problem, and care should be taken to avoid skin contact with the allergen by those administering the drugs.
Other treatments. A response to methotrexate (an immunosuppressant) has been reported in several case series [162] [163] [164] . However, many patients also received systemic corticosteroids, and owing to the lack of controls, this makes it difficult to assess the magnitude of any bene fit. Although a small case series suggests a response to cyclosporine (a calcineurin inhibitor), the benefits are probably too small and inconsistent to justify its use in view of the possible adverse effects 165 . Topical tacrolimus (an immunosuppressant) is ineffective 166 . With the exception of isolated case reports, anti-tumour necrosis factor biologic agents have not been shown to be effective for alopecia areata. An open-label study with etanercept revealed no efficacy in the treatment of moderate-tosevere alopecia areata 167 . In addition, patients who have been treated with adalimumab, infliximab or etanercept for other autoimmune disorders have developed alopecia areata during the course of treatment 168, 169 . Finally, small randomized trials of efalizumab (an anti-CD11a) 170 and alefacept (an anti-CD2) 171 showed no benefit in alopecia areata.
Non-medical treatments
Laser treatment. Laser therapy may have a positive effect on patients with alopecia areata. The excimer laser (an ultraviolet (UV) laser) is currently commonly used and may offer a safe and effective alternative to medical treatments. However, recent reviews and reports indicate that randomized controlled clinical trials are needed to confirm that this is a better approach than medical treatment, as the only result might be an increase in hair shaft diameter 172, 173 . Preclinical trials with the mouse model for alopecia areata did not show efficacy using a laser comb 174 . Photochemotherapy with all types of PUVA (oral or topical psoralen, local or whole-body UVA irradiation) claims success rates of up to 60-65% for alopecia areata in uncontrolled studies [175] [176] [177] , but results are inconsistent. Retrospective reviews reported low response rates 178 or response similar to the natural course of the disease 179 . Relapse rates are high and continued treatment is usually needed to maintain hair growth, which may lead to an unacceptably high cumulative UVA dose.
Cosmetic strategies. Women with extensive alopecia might decide to wear a wig, hairpiece or bandana. Men tend to shave their heads, although some opt for a wig. The use of semi-permanent tattooing can be helpful to disguise loss of eyebrows.
Psychological support. For many patients with extensive patchy alopecia areata, alopecia totalis or alopecia universalis, current medical treatments fail. The individual coping response to alopecia varies from the alopecia being an inconvenience that has little or no effect on leading a normal life through to a life-changing experience that can have a devastating effect on psycho logical well-being with consequences that include clinically significant depression, loss of employment and social isolation 180 . The clinician has an important role in recognizing the psychological effect of alopecia and in helping the patient to overcome and adapt to this issue. Some patients will need professional support from a clinical psychologist or other practitioner who is skilled in managing disfigurement. Many benefit from contact with patient support organizations, for example, the National Alopecia Areata Foundation (https://www. naaf.org) and Alopecia UK (http:// www. alopeciaonline. org.uk). In children, alopecia areata can be particularly difficult to deal with. If a parent feels that there is a considerable change in the needs of their child (withdrawn, low self-esteem, failing to achieve at school and/or change in behaviour) the child may need to be referred to a paediatric clinical psychologist, educational psychologist or social worker (https://www. naaf.org/alopecia-areata/living-with-alopecia-areata/ alopecia-areata-in-children) 137 .
Quality of life
Psychological stress levels, frequency of psychiatric disease and levels of psychiatric symptoms are usually reported to be higher in adult patients with alopecia areata than controls, but contradictory reports exist. In one study, 8.8% of patients with alopecia areata experience major depression throughout their lifetime, 18.2% experience generalized anxiety disorder, 3.5% experience social phobia and 4.4% experience paranoid disorder 19 . Another study reported that alopecia areata is associated with poor psychiatric status and QOL, especially in childhood 181 . This study indicated that children with alope cia areata were more likely to have a depressive mood than adolescents with alopecia areata. The explanation for this difference is not clear as the effect on the QOL of children and adolescents occurs through both clin ical and psychiatric parameters, which are very complicated 181 . More in-depth and accurate studies to identify which factors affect the QOL of patients with alopecia areata are needed.
The effects of alopecia, including alopecia areata, on physical health status are measured by morbidity and mortality data that are commonly used to evaluate health conditions, but the QOL of patients with alopecia may considerably differ 182, 183 
. The physical, mental and social aspects of a healthy person with alopecia are very different from those individuals with chronic medical or physical disability. Female pattern hair loss and alopecia areata do not cause physical disability but have mental and social effects that affect QOL 184 .
To address the need to better define factors that affect the QOL of patients with alopecia areata, selfassessment health instruments, such as the Dermatology Life Quality Index and the 36-Item Short Form Health Survey (SF-36), are used 5, 183 . Alopecia areata-specific instruments have also been developed, including the Alopecia Areata Quality of Life Index, Alopecia Areata Quality of Life and the Alopecia Areata Symptom Impact Scale 183 . Health-related QOL assessments using Skindex-16 (a brief version of the Feel of Negative Evaluation Scale and Dermatology Life Quality Index) of 532 patients enrolled in the US National Alopecia Areata Registry were compared to previously reported health-related QOL levels from healthy controls and patients with other skin diseases 5 . Risk factors for poor health-related QOL were 20-50 years of age, female sex, light skin colour, hair loss of 25-99% on the scalp surface, family stress and change in employment. Another study searched six electronic databases of 479 studies on the effects of alopecia areata on health-related QOL; 21 studies with 2,530 patients met the inclusion criteria 183 . The meta-analysis of SF-36 studies detected a significantly reduced health-related QOL across the role -emotional, mental health and vitality domains (P < 0.001). Scalp involvement, anxiety and depression had a negative effect on health-related QOL with conflicting results for age, sex, marital status and disease duration, but wearing a wig had a positive impact 183 . Alopecia areata has a profound effect on self-awareness owing to the psychological effect of negative beliefs and emotions 185 . More attention should be given to the effect of alopecia areata on QOL.
Outlook
Patient stratification
Textbooks list the numbers of patients tested in various studies, outcomes and effectiveness ratings for the classic types of alopecia areata
, and these patient categories still form the basis for treatment decisions to date 186 . Indeed, these broad subtypes have been used to stratify patients for treatment and clinical trials when little was known about the underlying pathophysiology of alopecia areata and when no biomarkers were available.
Future treatment strategies
There currently are no FDA-approved treatments for alopecia areata, although some European guidelines discuss treatment options 137 . No treatment approaches have been consistently effective in large numbers of patients. As the molecular mechanisms of alopecia areata are further defined and rationally designed trials are initiated, clinicians can consider using targeted thera pies. Adverse effects of many of these treatments are important considerations, but as more drugs are identi fied, it is possible that combinations at lower dosages and/or topical applications will achieve results with acceptable safety profiles. For a disease that has been largely untreatable, the exponential rate of progression in technological developments in the past 25 years indicates that efficacious therapies are possible in the foreseeable future.
Antibodies and biologics. The similarity of the molecular and clinical aspects of alopecia areata between humans and mice has integrated investigations between the species and has both revealed and validated potential targets. For example, the first transcriptome study of humans and mice identified a dysregulated transcript, CTLA4 in humans and Ctla4 in mice, which encodes cytotoxic T lymphocyte protein 4, a co-stimulatory T cell ligand that binds to CD80 (formerly B7.1) and CD86 (formerly B7.2) on antigen-presenting cells. As in other autoimmune diseases, this pathway can be targeted with recombinant CTLA4-immunoglobulin to treat alopecia areata 4, 57, 187, 188 . Increased expression of IFN-response genes (including CXCL9 (which encodes CXC-chemokine ligand 9), CXCL10 and CXCL11) was found in several human and mouse transcriptome studies 2, 58, 189, 190 . Monoclonal antibodies against these cytokines seem to be effective in mouse models, paving the way for additional clinical approaches to treating patients 191 . Patients with alopecia areata had a significant increase in the levels of IL-12 and IL-23 in their skin compared with normal patients who were treated with ustekinumab, a human monoclonal antibody that is targeted against these cytokines. This small series of patients had a gradual improvement at 20 and 28 weeks of treatment and full hair regrowth by week 49 (REF. 192 ). Secukinumab is a human IL-17A antagonist that is currently indicated for the treatment of adult patients with plaque psoriasis, active psoriatic arthritis and active ankylosing spondylitis. Clinical trials are in progress for using this drug to treat patients with alopecia areata 193 .
JAK inhibitors. The human genetic studies and gene expression analyses have revealed that molecular pathways upstream of JAKs were often disrupted in alopecia areata 4,42 (FIG. 2) . Several JAK inhibitors are approved by the FDA for clinical use for treating other diseases, such as myelofibrosis (ruxolitinib, a JAK1/2 inhibitor) and rheumatoid arthritis (tofacitinib, a pan-JAK inhibitor). These drugs have been shown to be effective in both preventing and reversing alopecia areata in preclinical trials using the C3H/HeJ mouse model, when given topically as well as orally 2 . Several case series and individual reports have documented regrowth of hair in patients with different forms of alopecia areata, including alope cia universalis, following treatment with oral JAK inhibitors. Three JAK inhibitors have been used: tofaciti nib [194] [195] [196] [197] [198] , ruxolitinib 2, 199, 200 and baricitinib (a JAK1/2 inhibitor) 201 . Hair regrowth has also been observed when treating human patients with JAK inhibitors for other diseases who have concurrent alopecia areata. Although the number of reports is small, and no randomized, placebo-controlled studies have yet been performed, the response in patients with severe alopecia areata (in which spontaneous remission is rare) strongly suggests a therapeutic effect. Not surprisingly, there have been several reports of relapse following initial improvement in patients who were treated with ruxolitinib and tofacitinib 196, 197, 200, 202 , suggesting that an eventual therapeutic regimen may need to include longterm mainten ance therapy. The overall positive results in these early clinical studies are supported by the results of JAK inhibition in a mouse model of alopecia areata and by an improved understanding of the pathogenesis of the disease. Several clinical trials are now underway to rigorously test the efficacy of oral and topical JAK inhibitors using larger and placebo-controlled studies.
Stem cell approaches. Stem cell educator therapy has shown some initial success 203 . This approach uses a closed-loop system to isolate mononuclear cells derived from patients with alopecia areata, allows them to interact with human cord blood-derived multipotent stem cells and then returns the 'educated' cells into the patient's circulation. Using this treatment, patients with severe alopecia areata had improvement in both hair regrowth and QOL. The underlying mechanism seemed to be the upregulation of T helper 2 (T H 2) cytokines and the restoration of balancing T H 1, T H 2 and T H 3 cytokine production.
Taken together, basic science approaches have identified a series of molecular targets, many of which already have approval in some countries. Combinations of these drugs may become commonly used to treat patients with alopecia areata in the not too distant future.
